Who was studied, and how
Three numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 19 other studies
306people with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
taspoglutide 10 mg once every 2 weeks
placebo
Reported lower A1C, no range given−0.70
randomisedThe trial randomly assignedassigned by chance
taspoglutide 10 mg once weekly
placebo
Reported lower A1C, no range given−1.00
randomisedthe abstract, start to end
… from a mean +/- SD baseline of 7.9 +/- 0.7% were observed in all taspoglutide groups compared with placebo after 8 weeks of treatment: -1.0 +/- 0.1% (5 mg once weekly), …
… groups and the 20 mg once every 2 weeks (-1.9 +/- 0.3 kg, P = …
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
Change in A1C (percent) from baselinetaspoglutide 10 mg once every 2 weeks vs placebo
−0.70
Change in A1C (percent) from baselinetaspoglutide 10 mg once weekly vs placebo
−1.0
Body weight losstaspoglutide 20 mg once weekly vs placebo
−2.00
Investigational compoundsGlycemic controlBody weight & composition
Investigational compounds × glycemic controlhelps?replicated
unlikelylikely
0.780.76 without it
Investigational compounds × body weight & compositionhelps?settled
unlikelylikely
1.001.00 without it
← favours treatmentfavours comparator →
1 / 6